VALISURE

Lobbying Spend

—

Filings

Firms Hired

Active Period

2019–2026

Lobbying Spend by Year

Client-reported lobbying expenses on LDA filings

Year	Lobbying Spend	Filings	Firms
2026	—	3	1
2025	—	4	1
2024	—	5	1
2022	—	3	1
2021	—	4	1
2020	—	4	1
2019	—	2	1

Lobbying firms retained by this client; amounts are client-reported expenses when available

Firm Name	Reported Spend	Filings
TODD STRATEGY GROUP	—	7
BAKER DONELSON BEARMAN CALDWELL & BERKOWITZ	—	13
DB3, LLC (FKA THE DASCHLE GROUP)	—	5

Government entities explicitly identified as targets in LDA filings

Government Body	Filings
HOUSE OF REPRESENTATIVES	17
SENATE	17
Health & Human Services, Dept of (HHS)	6
Executive Office of the President (EOP)	2

Most frequently reported lobbying issues

Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded

H.R. 3688118th Congress

Recall Unsafe Drugs Act of 2023

Cited source text and reported amounts

Issues related to drug quality; safety of the U.S. drug supply chain; H.R.3688, Recall Unsafe Drugs Act of 2023

Client expense: — · Firm income: —

Matched citations: H.R.3688

H.R. 3688118th Congress

Recall Unsafe Drugs Act of 2023

Cited source text and reported amounts

Issues related to drug quality; safety of the U.S. drug supply chain; H.R.3688, Recall Unsafe Drugs Act of 2023

Client expense: — · Firm income: —

Matched citations: H.R.3688

H.R. 3688118th Congress

Recall Unsafe Drugs Act of 2023

Cited source text and reported amounts

Issues related to drug quality; safety of the U.S. drug supply chain; H.R.3688, Recall Unsafe Drugs Act of 2023

Client expense: — · Firm income: —

Matched citations: H.R.3688

VALISURE — Lobbying Disclosure | Poliscope